This site is intended for Healthcare professionals only.

Glenmark gets USFDA nod for generic skin ointment

Glenmark gets USFDA nod for generic skin ointment

New Delhi: Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market Desonide Ointment, used to treat skin problems, in the American market.

Glenmark Pharmaceuticals Inc, a subsidiary of the company, has received final approval from the US Food and Drug Administration (USFDA) for Desonide ointment, the company said in a statement.

The Mumbai-based company’s product is the generic version of Perrigo New York Inc’s Desonide Ointment.

As per the latest IMS Health sales data, the product had annual sales of around USD 23.4 million.

Glenmark s current portfolio consists of 124 products authorized for distribution in the US marketplace and 62 ANDAs pending approval with the USFDA.

The following two tabs change content below.
Ruby Khatun

Ruby Khatun

Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at Contact no. 011-43720751

Source: PTI
0 comment(s) on Glenmark gets USFDA nod for generic skin ointment

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted